Eisai Golden Ticket and Plane-Lab-Experiment in one day!
 ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 
MBC Bio Labs
2021
September Newsletter
Events

Eisai Innovation Virtual Seminar on Its Inaugural Eisai Golden Ticket Competition
Please join us for a virtual seminar with Eisai Co., Ltd. And Eisai Innovation, Inc. to learn more about Eisai’s Inaugural Golden Ticket Competition and the company’s innovative activities, including Eisai’s R&D, therapeutics and technology focus area, business, partnering and investment strategy.
Click to Register
Golden Ticket

Eisai Innovation and MBC BioLabs Announce 2021 Eisai Golden Ticket Competition to Accelerate Early Drug Discovery and Research Efforts
Eisai Innovation, Inc. (EII), an affiliate of Eisai Co., Ltd. the fully integrated pharmaceutical company based in Tokyo, Japan, is partnering with MBC BioLabs to award one Golden Ticket to an innovative life science startup. Eisai is interested in drug discovery technologies, novel targets and biology that can be utilized in oncology and neurology.
Click to Apply
In The News

Asher Biotherapeutics has raised another $108 million in an oversubscribed Series B financing round.
Since entering the biotech arena five months ago with a $55 million funding round to develop a suite of immunotherapies that target specific cell types with cytokines, Asher Biotherapeutics has raised another $108 million in an oversubscribed Series B financing round.
Click to Read More
New Companies

resistanceBio can discover and overcome clinical treatment resistance
Cancer readily adapts to and resists treatment. Resistant cells become the prominent population in a tumor, creating an untreatable cancer. To prevent this outcome, resistanceBio has built a drug discovery pipeline capable of identifying a targeted multi-pronged attack that adapts to the tumor throughout treatment.
CLICK TO LEARN MORE
MBC BioLabs, Enabling Awesome